Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by Glaukos® Corporation as a...
Patients and their families who are facing a rare disease or complex condition require much more than just a prescription. They require ongoing support...
Hereditary Angioedema (HAE) is an inherited genetic disorder that can affect the autoimmune system causing recurrent episodes of severe swelling, most...
Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced that it has been selected by Alnylam® Pharmaceuticals as a limited...
When pharmaceutical manufacturers and providers are seeking a specialty pharmacy partner, it's important to look into the distinctions and...
Duchenne muscular dystrophy (DMD) is a genetic, progressive form of muscular dystrophy that occurs primarily in males. It is caused by genetic changes...
Specialty pharmacies are part of the patient care team and play a critical role in providing access and support to patients needing specialty...
Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by PTC Therapeutics, Inc. as a...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease